Pulmonx Corp. (LUNG) News

Pulmonx Corp. (LUNG): $16.66

-0.40 (-2.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter LUNG News Items

LUNG News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LUNG News Highlights

  • For LUNG, its 30 day story count is now at 2.
  • Over the past 16 days, the trend for LUNG's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest LUNG News From Around the Web

Below are the latest news stories about PULMONX CORP that investors may wish to consider to help them evaluate LUNG as an investment opportunity.

ADDING and REPLACING CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

REDWOOD CITY, Calif. & BARCELONA, Spain, September 09, 2022--CONVERT Clinical Trial Data Presented at ERS Demonstrates Early Success of AeriSeal System in Patients with Advanced COPD/Emphysema

Yahoo | September 9, 2022

Pulmonx to Present at Upcoming September Investor Conferences

REDWOOD CITY, Calif., August 24, 2022--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in fireside chats at two upcoming investor conferences. Pulmonx management is scheduled to participate in the 2022 Wells Fargo Healthcare Conference in Boston on Wednesday, September 7, 2022, at 6:10am PT / 9:10am ET and the Morgan Stanley 20th Annual Global Healthcare Conference in New Yo

Yahoo | August 24, 2022

Wall Street Analysts Predict a 79% Upside in Pulmonx Corporation (LUNG): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 78.6% in Pulmonx Corporation (LUNG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | August 3, 2022

Pulmonx Corporation (LUNG) Q2 2022 Earnings Call Transcript

Joining me from Pulmonx are Glen French, president and chief executive officer; and Derrick Sung, chief financial officer. Before we begin, I'd like to remind you that Management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor position of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to the expectations or predictions of future events, results or performance are forward-looking statements.

Yahoo | August 3, 2022

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 2.44% and 1.78%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 2, 2022

Pulmonx Reports Second Quarter 2022 Financial Results

REDWOOD CITY, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Achieved a new high in worldwide revenue of $14.0 million in the second quarter of 2022, a 14% increase over the same period last year and an increase of 19% on a constant currency basisRealized gross margin of 75% in

Yahoo | August 2, 2022

Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference

REDWOOD CITY, Calif., July 27, 2022--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 10, 2022, at 1:00 PM PT / 4:00 PM ET.

Yahoo | July 27, 2022

Pulmonx to Report Second Quarter 2022 Financial Results on August 2, 2022

REDWOOD CITY, Calif., July 19, 2022--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Tuesday, August 2, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Yahoo | July 19, 2022

Can Pulmonx Corporation (LUNG) Climb 117% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at an 117.5% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | July 18, 2022

Analysts Just Trimmed Their Price Targets of These 10 Stocks

In this article, we will take a look at the 10 stocks that recently received price-target cuts from analysts. If you want to see some other companies receiving downgrades, go directly to Analysts Just Trimmed Their Price Targets of These 5 Stocks. The Bureau of Labor Statistics recently released the inflation report, stating that inflation […]

Yahoo | July 18, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4744 seconds.